Skip to Content
Merck
All Photos(2)

Documents

RAB0195

Sigma-Aldrich

Human VEGF R3 ELISA Kit

for serum, plasma, cell culture supernatant, urine

Sign Into View Organizational & Contract Pricing


About This Item

UNSPSC Code:
41116158
NACRES:
NA.32

species reactivity

human

packaging

kit of 96 wells (12 strips x 8 wells)

technique(s)

ELISA: suitable
capture ELISA: suitable

input

sample type serum
sample type cell culture supernatant(s)
sample type plasma
sample type urine

assay range

inter-assay cv: <12%
intra-assay cv: <10%
sensitivity: 15 pg/mL
standard curve range: 12.29-3000 pg/mL

detection method

colorimetric

shipped in

wet ice

storage temp.

−20°C

Gene Information

human ... FLT4(2324)

General description

The Human VEGF R3 (Vascular Endothelial Growth Factor Receptor 3) ELISA (Enzyme-Linked Immunosorbent Assay) kit is an in vitro enzyme-linked immunosorbent assay for the quantitative measurement of human VEGF R3 in serum, plasma, cell culture supernatants and urine.

Immunogen

Recombinant Human VEGFR3

Application

For research use only. Not for use in diagnostic procedures.
Please refer to the attached General ELISA KIT Procedure (sandwich, competitive & Indirect ELISA)

Other Notes

A sample Certificate of Analysis is available for this product.
Please type the word sample in the text box provided for lot number.

Kit Components Also Available Separately

Product No.
Description
SDS

  • RABELADAELISA 1X Assay/Sample Diluent Buffer A (Item D1)SDS

  • RABELADBELISA 5X Assay/Sample Diluent Buffer B (Item E1)SDS

  • RABSTOP3ELISA Stop Solution (Item I)SDS

  • RABTMB3ELISA Colorimetric TMB Reagent (HRP Substrate, Item H)SDS

  • RABWASH420X Wash Buffer (Item B)SDS

Pictograms

Corrosion

Signal Word

Warning

Hazard Statements

Precautionary Statements

Hazard Classifications

Met. Corr. 1

Storage Class Code

8A - Combustible corrosive hazardous materials


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Fumitaka Shimizu et al.
PloS one, 9(3), e92872-e92872 (2014-04-02)
Pathological destruction of blood-brain barrier (BBB) has been thought to be the initial key event in the process of developing multiple sclerosis (MS). The purpose of the present study was to clarify the possible molecular mechanisms responsible for the malfunction
Teng Jiang et al.
British journal of pharmacology, 171(18), 4222-4232 (2014-05-16)
As a newer component of the renin-angiotensin system, angiotensin-(1-7) [Ang-(1-7) ] has been shown to facilitate angiogenesis and protect against ischaemic damage in peripheral tissues. However, the role of Ang-(1-7) in brain angiogenesis remains unclear. The aim of this study was
Alexa Klettner et al.
Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 252(10), 1593-1598 (2014-07-23)
Anti-VEGF treatment is the therapy of choice in age-related macular degeneration and is also applied in diabetic macular edema or retinal vein occlusion. Recently, aflibercept has been approved for therapeutic use. In this study, we investigate the efficacy of aflibercept
Guodong Zhang et al.
Proceedings of the National Academy of Sciences of the United States of America, 111(30), 11127-11132 (2014-07-16)
Prostaglandins derived from the cyclooxygenase (COX) pathway and epoxyeicosatrienoic acids (EETs) from the cytochrome P450/soluble epoxide hydrolase (sEH) pathway are important eicosanoids that regulate angiogenesis and tumorigenesis. COX-2 inhibitors, which block the formation of prostaglandins, suppress tumor growth, whereas sEH
Raimo Tuuminen et al.
Acta ophthalmologica, 92(7), 675-681 (2014-02-11)
To investigate the intravitreal levels of potent vasoactive, angiogenic and extracellular matrix remodelling factors in the diabetic patients with simvastatin treatment. This is an institutional, prospective, observational case-control study. Type-1 and type-2 diabetic patients on lipophilic simvastatin (N = 14)

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service